View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 02, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity File Number	001-16537
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		61,724,870

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 72,567	$ 88,438
Short-term investments	74,446	68,134
Accounts receivable, net of allowance for doubtful accounts of $571 and $418	29,390	34,842
Inventories	25,670	22,888
Prepaid expenses	2,128	1,925
Other current assets	5,057	3,085
Total current assets	209,258	219,312
Noncurrent Assets:
Property, plant and equipment, net	27,793	24,299
Operating right-of-use assets, net	3,685
Finance right-of-use assets, net	1,462
Intangible assets, net	12,472	5,137
Goodwill	29,280	18,521
Long-term investments	39,555	44,752
Other noncurrent assets	3,960	3,550
Total noncurrent assets	118,207	96,259
TOTAL ASSETS	327,465	315,571
Current Liabilities:
Accounts payable	10,956	10,598
Deferred revenue	3,914	3,521
Accrued expenses	8,638	13,861
Finance lease liability	448
Operating lease liability	746
Acquisition-related contingent consideration obligation	5,249
Total current liabilities	29,951	27,980
Noncurrent Liabilities:
Finance lease liability	930
Operating lease liability	3,266
Acquisition-related contingent consideration obligation	649
Other noncurrent liabilities	3,538	3,312
Deferred income taxes	910	901
Total noncurrent liabilities	9,293	4,213
TOTAL LIABILITIES	39,244	32,193
Commitments and contingencies (Note 10)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 61,725 and 61,276 shares issued and outstanding	0	0
Additional paid-in capital	399,585	401,273
Accumulated other comprehensive loss	(13,315)	(18,706)
Accumulated deficit	(98,049)	(99,189)
Total stockholders' equity	288,221	283,378
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 327,465	$ 315,571

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 571	$ 418
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	61,725,000	61,276,000
Common stock, shares outstanding	61,725,000	61,276,000

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
NET REVENUES:
Total revenue	$ 38,826	$ 43,625	$ 68,948	$ 85,612
COST OF PRODUCTS SOLD	13,808	17,730	25,850	35,250
Gross profit	25,018	25,895	43,098	50,362
OPERATING EXPENSES:
Research and development	4,535	4,261	8,906	8,336
Sales and marketing	7,687	7,429	14,982	14,928
General and administrative	7,262	8,647	16,192	22,038
Change in the estimated fair value of acquisition-related contingent consideration	249		1,544
Total operating expenses	19,733	20,337	41,624	45,302
Operating income	5,285	5,558	1,474	5,060
OTHER INCOME	524	736	1,048	1,148
Income before income taxes	5,809	6,294	2,522	6,208
INCOME TAX EXPENSE	1,411	2,173	1,382	4,206
NET INCOME	$ 4,398	$ 4,121	$ 1,140	$ 2,002
EARNINGS PER SHARE:
BASIC	$ 0.07	$ 0.07	$ 0.02	$ 0.03
DILUTED	$ 0.07	$ 0.07	$ 0.02	$ 0.03
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	61,709	61,100	61,621	60,983
DILUTED	62,128	62,244	62,191	62,379
Products and Services [Member]
NET REVENUES:
Total revenue	$ 37,267	$ 38,818	$ 65,599	$ 77,136
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 1,559	$ 4,807	$ 3,349	$ 8,476

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME	$ 4,398	$ 4,121	$ 1,140	$ 2,002
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	2,476	(1,652)	4,708	(3,806)
Unrealized gain (loss) on marketable securities	186	194	683	(318)
COMPREHENSIVE INCOME (LOSS)	$ 7,060	$ 2,663	$ 6,531	$ (2,122)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
OPERATING ACTIVITIES:
Net income	$ 1,140	$ 2,002
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	1,848	11,262
Depreciation and amortization	3,610	3,746
Unrealized foreign currency (gain)/loss	365	(255)
Interest expense on finance leases	13
Deferred income taxes	(467)	(272)
Change in the estimated fair value of acquisition-related contingent consideration	1,544
Changes in assets and liabilities
Accounts receivable	6,175	10,166
Inventories	(2,298)	(1,429)
Prepaid expenses and other assets	632	289
Accounts payable	81	(193)
Deferred revenue	301	253
Accrued expenses and other liabilities	(8,283)	(11,641)
Net cash provided by operating activities	4,661	13,928
INVESTING ACTIVITIES:
Purchases of investments	(55,317)	(93,917)
Proceeds from maturities and redemptions of investments	55,624	85,926
Purchases of property and equipment	(5,513)	(4,484)
Acquisition of businesses, net of cash acquired	(13,217)
Net cash used in investing activities	(18,423)	(12,475)
FINANCING ACTIVITIES:
Repayments of loans	(724)
Cash payments for lease liability	(124)
Proceeds from exercise of stock options	169	1,201
Repurchase of common stock	(3,704)	(3,171)
Net cash used in financing activities	(4,383)	(1,970)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	2,274	(1,283)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(15,871)	(1,800)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	88,438	72,869
CASH AND CASH EQUIVALENTS, END OF PERIOD	72,567	71,069
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	6,097	11,159
Non-cash investing and financing activities
Accrued property and equipment purchases	490	665
Unrealized gain (loss) on marketable securities	$ 683	$ (318)

The Company

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

1.	The Company

Our business is composed of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular collections systems or “DNAG” business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets, and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets.

Our OSUR diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. We also manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery or freezing. These cryosurgical products are sold in both professional and over-the-counter (“OTC”) markets in North America, Europe, Central and South America, and Australia.

Our DNAG or molecular collection systems business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), CoreBiome Inc. (“CoreBiome”), and Novosanis NV (“Novosanis”). DNAG’s specimen collection devices provide all-in-one systems for the collection, stabilization, transportation and storage of nucleic acids from human saliva and other sample types for genetic and microbiome applications. Novosanis’ Colli-Pee collection device is designed for the volumetric collection of first-void urine for use in research, screening and diagnostics for the liquid biopsy and sexually transmitted disease markets. We also sell research use only sample collection products into the microbiome and tuberculosis markets and we offer our customers a suite of genomics and microbiome services, which range from package customization and study design optimization to extraction, analysis and reporting services. We serve customers worldwide in the research, healthcare, pharmaceutical and agricultural communities.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, CoreBiome, and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual report on Form 10-K for the fiscal year ended December 31, 2018. Results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, contingent consideration, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Investments. We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale debt securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The following is a summary of our available-for-sale securities as of June 30, 2019 and December 31, 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2019
Guaranteed investment certificates	$	24,193	$	—	$	—		$	24,193
Corporate bonds		90,042		230		(464	)		89,808
Total available-for-sale securities	$	114,235	$	230	$	(464	)	$	114,001
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At June 30, 2019, maturities of our available-for-sale securities were as follows:
Less than one year	$	74,710	$	141	$	(405	)	$	74,446
Greater than one year	$	39,525	$	89	$	(59	)	$	39,555

Fair Value of Financial Instruments. As of June 30, 2019 and December 31, 2018, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 1 instruments as of June 30, 2019 and December 31, 2018.

Included in cash and cash equivalents at June 30, 2019 and December 31, 2018, was $7,399 and $21,631 invested in government money market funds and certificates of deposit. Both are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of June 30, 2019 and December 31, 2018 was $4,227 and $3,884, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

See Note 3 for discussion of the contingent consideration liabilities.

Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials	$	15,551	$	14,092
Work in process		650		544
Finished goods		9,469		8,252
	$	25,670	$	22,888

Property, Plant and Equipment. Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of June 30, 2019 and December 31, 2018 was $45,040 and $42,797, respectively.

Intangible Assets. Intangible assets consist of customer lists, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of June 30, 2019 and December 31, 2018 was $21,984 and $20,105, respectively. The change in intangibles from $5,137 as of December 31, 2018 to $12,472 as of June 30, 2019 is a result of intangibles acquired in our acquisitions of CoreBiome and Novosanis of $8,400 and $163 in foreign currency translation gains, partially offset by $1,228 in amortization expense.

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisitions of DNAG, CoreBiome, and Novosanis. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The increase in goodwill from $18,521 as of December 31, 2018 to $29,280 as of June 30, 2019 is a result of the additional goodwill associated with our acquisitions of CoreBiome and Novosanis of $9,994 and an increase of $765 associated with foreign currency translation. All acquired goodwill has been allocated to our DNAG segment.

Leases. In February 2016, the FASB issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and will not restate comparative amounts. Also, we elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classification, our assessment on whether a contract is or contains a lease, and our initial direct costs for any leases that exist prior to adoption of the new standard. Leases with an initial term of 12 months or less are not recognized on the balance sheet and the associated lease payments are included in the consolidated statements of operations on a straight-line basis over the lease term. As a result, on January 1, 2019, we recorded right-of-use assets of $4,027 and lease liabilities of $4,263 on our consolidated balance sheet.

Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:

	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2019		2018		2019		2018

Net income	$	4,398	$	4,121	$	1,140	$	2,002
Weighted-average shares of common stock outstanding:
Basic		61,709		61,100		61,621		60,983
Dilutive effect of stock options, restricted stock, and performance stock units		419		1,144		570		1,396
Diluted		62,128		62,244		62,191		62,379
Earnings per share:
Basic	$	0.07	$	0.07	$	0.02	$	0.03
Diluted	$	0.07	$	0.07	$	0.02	$	0.03

For the three months ended June 30, 2019 and 2018, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 698 and 210 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the six months ended June 30, 2019 and 2018, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 222 and 205 shares, respectively, were similarly excluded from the computation of diluted earnings per share.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in our consolidated statements of operations were $(317) and $91 for the three months ended June 30, 2019 and 2018, respectively. Net foreign exchange gains (losses) were $(926) and $345 for the six months ended June 30, 2019 and 2018, respectively.

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at June 30, 2019 consists of $13,081 of currency translation adjustments and $234 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2018 consists of $17,789 of currency translation adjustments and $917 of net unrealized losses on marketable securities.

Recent Accounting Pronouncements

In June 2016, the FASB issued guidance on the measurement of credit losses, which requires measurement and recognition of expected credit losses for financial assets, including trade receivables and capital lease receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. The guidance is effective beginning in fiscal year 2020, with early adoption permitted beginning in fiscal year 2020. We are evaluating the impact this guidance will have on our consolidated financial statements.

In February 2018, the FASB issued guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the U.S. Tax Cuts and Jobs Act. The guidance is effective in fiscal year 2020, with early adoption permitted, including adoption in an interim period. If elected, the reclassification can be applied in either the period of adoption or retrospectively to the period of the enactment of the U.S. Tax Cuts and Jobs Act (i.e., our first quarter of fiscal year 2018). We are evaluating the impact of this guidance and expect no impact to our consolidated financial statements.

Business Combinations

6 Months Ended

Jun. 30, 2019

Business Combinations [Abstract]

Business Combinations

3. Business Combinations

On January 4, 2019, the Company acquired all of the outstanding stock of CoreBiome, pursuant to the terms of a merger agreement, dated January 3, 2019. Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis, pursuant to a share purchase agreement, dated January 3, 2019. We began operating these entities as of the January 4, 2019 closing date. The aggregate purchase price for both of these transactions was $13,320 adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, in order to secure the potential payment of certain indemnification obligations of the selling stockholders under each agreement noted above.

During the six months ended June 30, 2019, we incurred a total of $597 of acquisition-related costs, including success-based investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of income.

Pursuant to our acquisition agreements, we may pay up to an additional $32,400 of contingent consideration over the next three years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, the achievement of a large customer contract, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $4,350. The simulation calculates the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not

observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is reviewed quarterly over the earn-out period to compare actual results with the estimates used in our forecasts. The change in the fair value of the contingent consideration obligation from $4,350 as of the acquisition date to $5,898 as of June 30, 2019 is a result of changes in our estimated revenue forecasts and the probability of achieving certain technical milestones.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		9,994
Total assets acquired		19,996
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		445
Other long-term liabilities		74
Total liabilities assumed		2,429
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of CoreBiome and Novosanis. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our DNAG segment.

We continue to evaluate the fair value of certain assets acquired and liabilities assumed, including the fair valuation of deferred tax assets acquired, related to the acquisition. Additional information, which existed as of the acquisition date, but was at that time unknown to us, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in

a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Revenues from CoreBiome primarily consist of microbiome laboratory services that utilize optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics. Revenues from Novosanis primarily consist of the sale of its Colli-Pee collection device which was designed for the standard collection of first-void urine used in the liquid biopsy and sexually transmitted infection screening market. For the three and six months ended June 30, 2019, combined revenues of $907 and $2,046 and net losses of $1,112 and $2,613 associated with the operations of CoreBiome and Novosanis, were included in our consolidated statement of operations since the acquisition date. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our DNAG segment.

Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the CoreBiome and Novosanis acquisitions as if they had been consummated as of January 1, 2018. The unaudited pro forma results include the amortization associated with acquired intangible assets and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of our contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2018.

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018

Revenue	$	38,826	$	44,129	$	68,948	$	86,522
Net income (loss)		4,398		3,179		1,737		(314	)
Net income (loss) per share, basic and diluted		0.07		0.05		0.03		(0.01	)

Revenues

6 Months Ended

Jun. 30, 2019

Revenue From Contract With Customer [Abstract]

Revenues

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
OraQuick®	$	12,967	$	15,791	$	24,557	$	28,796
Oragene®		10,904		14,421		15,726		30,349
ORAcollect®		3,318		947		6,543		2,107
Intercept®		2,070		2,154		3,914		4,069
Histofreezer®		2,935		1,973		5,149		4,327
Other products		5,073		3,532		9,710		7,488
Net product revenues		37,267		38,818		65,599		77,136

Royalty income		1,114		2,092		2,198		3,694
Research and development funding		441		1,920		862		3,458
Charitable support reimbursement		-		795		118		1,324
Grant funding		4		-		171
Other revenues		1,559		4,807		3,349		8,476
Net revenues	$	38,826	$	43,625	$	68,948	$	85,612

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
United States	$	27,902	$	31,991	$	48,467	$	62,977
Europe		2,990		2,308		5,421		5,205
Other regions		7,934		9,326		15,060		17,430
	$	38,826	$	43,625	$	68,948	$	85,612

Customer and Vendor Concentrations. We had no significant customer concentrations (greater than 10%) in accounts receivable as of June 30, 2019 or December 31, 2018, respectively. One of our customers accounted for approximately 13% of our net consolidated revenues for the three

months ended June 30, 2019. We had no customer concentrations in our net consolidated revenues for the six months ended June 30, 2019. One of our customers accounted for approximately 18% and 21% of our net consolidated revenues for the three and six months ended June 30, 2018.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June 30, 2019 and December 31, 2018 includes customer prepayments of $2,291 and $2,057, respectively. Deferred revenue as of June 30, 2019 and December 31, 2018 also includes $ 1,623 and $1,464, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that rate.

Accrued Expenses

6 Months Ended

Jun. 30, 2019

Payables And Accruals [Abstract]

Accrued Expenses

5.	Accrued Expenses

	June 30, 2019		December 31, 2018
Payroll and related benefits	$	5,413	$	8,926
Professional fees		1,160		1,541
Income taxes payable		—		1,447
Other		2,065		1,947
	$	8,638	$	13,861

Credit Facility

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Credit Facility

6.	Credit Facility

On March 29, 2019, we terminated our credit agreement with a commercial bank which was entered into on September 30, 2016 and had a maturity date of September 30, 2019.

Leases

6 Months Ended

Jun. 30, 2019

Lessee Disclosure [Abstract]

Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and will not restate comparative amounts.

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of June 30, 2019, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 8 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.

The components of lease expense are as follows:

	Three months ended		Six months ended
	June 30, 2019		June 30, 2019
Operating Lease Cost	$	232	$	463
Finance Lease Cost
Amortization of right-of use assets		113		152
Interest on lease liabilities		9		13
Total Finance Lease Cost	$	122	$	165

Lease cost for the three and six months ended June 30, 2018 was $388 and $730.

Supplemental cash flow information related to leases is as follows:

	Three months ended		Six months ended
	June 30, 2019		June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	230	$	458
Operating cash flows from financing leases		10		13
Financing cash flows from financing leases		89		124
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		-		240
Right-of-use assets obtained in exchange for finance lease obligations		82		1,249

Supplemental balance sheet information related to leases is as follows:

	June 30, 2019
Operating Leases
Right-of-use assets	$	3,685

Current lease liabilities		746
Non-current lease liabilities		3,266
Total operating lease liabilities	$	4,012


Finance Leases
Right-of-use assets	$	1,462

Current lease liabilities		448
Non-current lease liabilities		930
Total finance lease liabilities	$	1,378

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5.11
Weighted-average remaining lease term—finance leases	3.46

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.24	%
Weighted-average discount rate—finance leases	2.86	%

As of June 30, 2019, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2019 (excluding the six months ended June 30, 2019)	$	240		$	465
2020		454			957
2021		325			928
2022		324			903
2023		94			543
Thereafter		4			815
Total Minimum Lease Payments		1,441			4,611
Less: imputed interest		(63	)		(599	)
Present Value of Lease Liabilities	$	1,378		$	4,012

As of December 31, 2018, minimum lease payments under non-cancelable operating leases by period were expected to be as follows:

2019	$	903
2020		902
2021		877
2022		850
2023		506
Thereafter		737
	$	4,775

Stockholders' Equity

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Stockholders' Equity

8.	Stockholders’ Equity

Reconciliation of the changes in stockholders' equity for the three and six months ended June 30, 2019 and 2018
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2018		61,276		$	—	$	401,273		$	(18,706	)	$	(99,189	)	$	283,378
Common stock issued upon exercise of options		4			—		22			—			—			22
Vesting of restricted stock and performance stock units		664			—		—			—			—			—
Purchase and retirement of common shares		(277	)		—		(3,595	)		—			—			(3,595	)
Compensation cost for restricted stock		—			—		653			—			—			653
Compensation cost for stock option grants		—			—		324			—			—			324
Compensation cost for performance stock units		—			—		254			—			—			254
Net loss		—			—		—			—			(3,258	)		(3,258	)
Currency translation adjustments										2,232						2,232
Unrealized gain on marketable securities		—			—		—			497			—			497
Balance at March 31, 2019		61,667		$	—	$	398,931		$	(15,977	)	$	(102,447	)	$	280,507
Common stock issued upon exercise of options		18			—		147			—			—			147
Vesting of restricted stock and performance stock units		51			—		—			—			—			—
Purchase and retirement of common shares		(11	)		—		(109	)		—			—			(109	)
Compensation cost for restricted stock		—			—		874			—			—			874
Compensation cost for stock option grants		—			—		311			—			—			311
Compensation cost for performance stock units		—			—		(569	)		—			—			(569	)
Net income		—			—		—			—			4,398			4,398
Currency translation adjustments										2,476						2,476
Unrealized gain on marketable securities		—			—		—			186			—			186
Balance at June 30, 2019		61,725		$	—	$	399,585		$	(13,315	)	$	(98,049	)	$	288,221


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2017		60,662		$	—	$	387,931		$	(10,340	)	$	(119,510	)	$	258,081

Adoption of ASU 2014-9													(75	)		(75	)
Common stock issued upon exercise of options		133			—		974			—			—			974
Vesting of restricted stock and performance stock units		407			—		—			—			—			—
Purchase and retirement of common shares		(149	)		—		(2,959	)		—			—			(2,959	)
Compensation cost for restricted stock		—			—		3,626			—			—			3,626
Compensation cost for stock option grants		—			—		900			—			—			900

Compensation cost for performance stock units		—			—		2,957			—			—			2,957
Net loss		—			—		—			—			(2,119	)		(2,119	)
Currency translation adjustments										(2,154	)					(2,154	)
Unrealized loss on marketable securities		—			—		—			(512	)		—			(512	)
Balance at March 31, 2018		61,053		$	—	$	393,429		$	(13,006	)	$	(121,704	)	$	258,719
Adoption of ASU 2014-9																—
Common stock issued upon exercise of options		29			—		222			—			—			222
Vesting of restricted stock and performance stock units		106			—		—			—			—			—
Purchase and retirement of common shares		(14	)		—		(212	)		—			—			(212	)
Compensation cost for restricted stock		—			—		1,419			—			—			1,419
Compensation cost for stock option grants		—			—		475			—			—			475

Compensation cost for performance stock units		—			—		1,885			—			—			1,885
Net income		—			—		—			—			4,121			4,121
Currency translation adjustments										(1,652	)					(1,652	)
Unrealized gain on marketable securities		—			—		—			194			—			194
Balance at June 30, 2018		61,174		$	—	$	397,218		$	(14,464	)	$	(117,583	)	$	265,171

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market.

Total compensation cost related to stock options for the six months ended June 30, 2019 and 2018 was $635 and $1,375 respectively.

Compensation cost of $1,527 and $5,045 related to restricted shares was recognized during the six months ended June 30, 2019 and 2018, respectively. In connection with the vesting of restricted shares during the six months ended June 30, 2019 and 2018, we purchased and immediately retired 288 and 163 shares with aggregate values of $3,704 and $3,171, respectively, in satisfaction of minimum tax withholding obligations.

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in our service for three years from the grant date. Performance during the one-year period is based on a one-year earnings per share or income before income taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested.

Compensation cost of $(315) and $4,842 related to PSUs was recognized during the six months ended June 30, 2019 and 2018, respectively.

Modification of Grants

Stock compensation costs for the three and six months ended June 30, 2018 include the additional expense associated with modifications of existing grants held by our retired President and Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”). These additional costs were $2,188 and $8,039 during the three and six months ended June 30, 2018, respectively, and are included in general and administrative expenses in the accompanying consolidated statement of income.

Stock Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the six months ended June 30, 2019 and 2018.

Income Taxes

6 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

9.	Income Taxes

During the three and six months ended June 30, 2019, we recorded income tax expense of $1,411 and $1,382, respectively. During the three and six months ended June 30, 2018, we recorded tax expense of $2,173 and $4,206, respectively.

Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of June 30, 2019 and December 31, 2018 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes.

In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both June 30, 2019 and December 31, 2018 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state deferred income tax expense or benefit was recorded for the three and six month period ended June 30, 2019.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

10.	Commitments and Contingencies

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Transition Costs

6 Months Ended

Jun. 30, 2019

Transition Costs [Abstract]

Transition Costs

11.	Transition Costs

In January 2018, we announced the retirement of Douglas A. Michels, our then President and CEO, and Ronald H. Spair, our then CFO and Chief Operating Officer. Stephen S. Tang, Ph.D., who served as Chairman of the Board of Directors (the “Board”), was appointed as the Company’s new President and CEO, effective as of April 1, 2018. Dr. Tang replaced Mr. Michels, who retired as President and CEO, and as a member of the Board, on March 31, 2018. In addition, Roberto Cuca was appointed as the Company’s new CFO, effective June 8, 2018. Mr. Cuca replaced Mr. Spair, who retired as CFO and Chief Operating Officer, and as a member of our Board of Directors, on that same date. Charges associated with these transitions were $2,188 and $8,628 during the three and six months ended June 30, 2018 and are included in general and administrative expenses in the accompanying consolidated statement of income. These charges primarily reflect non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company’s new President and CEO. No related transition costs were recorded during the three and six months ended June 30, 2019.

Business Segment Information

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Business Segment Information

12.	Business Segment Information

Our business consists of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular collections systems or “DNAG” business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic

material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our DNAG segment.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

Operating income (loss) for the three and six months ended June 30, 2018 has been modified to conform to the classification of the intercompany service fee presentation for 2019. Beginning with the first quarter of 2019, we have included the fees for intercompany services in our segment operating income (loss) in order to more accurately reflect the results of each segment.

The following table summarizes operating segment information for the three and six months ended June 30, 2019 and 2018, and asset information as of June 30, 2019 and December 31, 2018:

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019			2018
Net revenues:
OSUR	$	20,372	$	24,341		$	38,605		$	46,365
DNAG		18,454		19,284			30,343			39,247
Total	$	38,826	$	43,625		$	68,948		$	85,612
Operating income (loss):
OSUR	$	14	$	(2,666	)	$	(3,485	)	$	(11,310	)
DNAG		5,271		8,224			4,959			16,370
Total	$	5,285	$	5,558		$	1,474		$	5,060
Depreciation and amortization:
OSUR	$	844	$	993		$	1,666		$	2,004
DNAG		1,040		885			1,944			1,742
Total	$	1,884	$	1,878		$	3,610		$	3,746
Capital expenditures:
OSUR	$	1,616	$	1,358		$	3,545		$	2,774
DNAG		1,269		1,229			1,968			1,710
Total	$	2,885	$	2,587		$	5,513		$	4,484

	June 30, 2019		December 31, 2018
Total assets:
OSUR	$	173,390	$	190,178
DNAG		154,075		125,393
Total	$	327,465	$	315,571

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Investments

The following is a summary of our available-for-sale securities as of June 30, 2019 and December 31, 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2019
Guaranteed investment certificates	$	24,193	$	—	$	—		$	24,193
Corporate bonds		90,042		230		(464	)		89,808
Total available-for-sale securities	$	114,235	$	230	$	(464	)	$	114,001
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At June 30, 2019, maturities of our available-for-sale securities were as follows:
Less than one year	$	74,710	$	141	$	(405	)	$	74,446
Greater than one year	$	39,525	$	89	$	(59	)	$	39,555

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 1 instruments as of June 30, 2019 and December 31, 2018.

See Note 3 for discussion of the contingent consideration liabilities.

Accounts Receivable

Inventories

Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials	$	15,551	$	14,092
Work in process		650		544
Finished goods		9,469		8,252
	$	25,670	$	22,888

Property, Plant and Equipment

The computations of basic and diluted earnings per share are as follows:

	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2019		2018		2019		2018

Net income	$	4,398	$	4,121	$	1,140	$	2,002
Weighted-average shares of common stock outstanding:
Basic		61,709		61,100		61,621		60,983
Dilutive effect of stock options, restricted stock, and performance stock units		419		1,144		570		1,396
Diluted		62,128		62,244		62,191		62,379
Earnings per share:
Basic	$	0.07	$	0.07	$	0.02	$	0.03
Diluted	$	0.07	$	0.07	$	0.02	$	0.03

Foreign Currency Translation

Accumulated Other Comprehensive Income (Loss)

Recent Accounting Pronouncements

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
OraQuick®	$	12,967	$	15,791	$	24,557	$	28,796
Oragene®		10,904		14,421		15,726		30,349
ORAcollect®		3,318		947		6,543		2,107
Intercept®		2,070		2,154		3,914		4,069
Histofreezer®		2,935		1,973		5,149		4,327
Other products		5,073		3,532		9,710		7,488
Net product revenues		37,267		38,818		65,599		77,136

Royalty income		1,114		2,092		2,198		3,694
Research and development funding		441		1,920		862		3,458
Charitable support reimbursement		-		795		118		1,324
Grant funding		4		-		171
Other revenues		1,559		4,807		3,349		8,476
Net revenues	$	38,826	$	43,625	$	68,948	$	85,612

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
United States	$	27,902	$	31,991	$	48,467	$	62,977
Europe		2,990		2,308		5,421		5,205
Other regions		7,934		9,326		15,060		17,430
	$	38,826	$	43,625	$	68,948	$	85,612

Customer and Vendor Concentrations

Deferred Revenue

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of June 30, 2019 and December 31, 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2019
Guaranteed investment certificates	$	24,193	$	—	$	—		$	24,193
Corporate bonds		90,042		230		(464	)		89,808
Total available-for-sale securities	$	114,235	$	230	$	(464	)	$	114,001
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At June 30, 2019, maturities of our available-for-sale securities were as follows:
Less than one year	$	74,710	$	141	$	(405	)	$	74,446
Greater than one year	$	39,525	$	89	$	(59	)	$	39,555

Schedule of Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials	$	15,551	$	14,092
Work in process		650		544
Finished goods		9,469		8,252
	$	25,670	$	22,888

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings per share are as follows:

	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2019		2018		2019		2018

Net income	$	4,398	$	4,121	$	1,140	$	2,002
Weighted-average shares of common stock outstanding:
Basic		61,709		61,100		61,621		60,983
Dilutive effect of stock options, restricted stock, and performance stock units		419		1,144		570		1,396
Diluted		62,128		62,244		62,191		62,379
Earnings per share:
Basic	$	0.07	$	0.07	$	0.02	$	0.03
Diluted	$	0.07	$	0.07	$	0.02	$	0.03

Business Combinations (Tables)

6 Months Ended

Jun. 30, 2019

Business Combinations [Abstract]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		9,994
Total assets acquired		19,996
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		445
Other long-term liabilities		74
Total liabilities assumed		2,429
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

Summary of Unaudited Pro Forma Financial Information

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018

Revenue	$	38,826	$	44,129	$	68,948	$	86,522
Net income (loss)		4,398		3,179		1,737		(314	)
Net income (loss) per share, basic and diluted		0.07		0.05		0.03		(0.01	)

Revenues (Tables)

6 Months Ended

Jun. 30, 2019

Revenue From Contract With Customer [Abstract]

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
OraQuick®	$	12,967	$	15,791	$	24,557	$	28,796
Oragene®		10,904		14,421		15,726		30,349
ORAcollect®		3,318		947		6,543		2,107
Intercept®		2,070		2,154		3,914		4,069
Histofreezer®		2,935		1,973		5,149		4,327
Other products		5,073		3,532		9,710		7,488
Net product revenues		37,267		38,818		65,599		77,136

Royalty income		1,114		2,092		2,198		3,694
Research and development funding		441		1,920		862		3,458
Charitable support reimbursement		-		795		118		1,324
Grant funding		4		-		171
Other revenues		1,559		4,807		3,349		8,476
Net revenues	$	38,826	$	43,625	$	68,948	$	85,612

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
United States	$	27,902	$	31,991	$	48,467	$	62,977
Europe		2,990		2,308		5,421		5,205
Other regions		7,934		9,326		15,060		17,430
	$	38,826	$	43,625	$	68,948	$	85,612

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2019

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

	June 30, 2019		December 31, 2018
Payroll and related benefits	$	5,413	$	8,926
Professional fees		1,160		1,541
Income taxes payable		—		1,447
Other		2,065		1,947
	$	8,638	$	13,861

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:

	Three months ended		Six months ended
	June 30, 2019		June 30, 2019
Operating Lease Cost	$	232	$	463
Finance Lease Cost
Amortization of right-of use assets		113		152
Interest on lease liabilities		9		13
Total Finance Lease Cost	$	122	$	165

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:

	Three months ended		Six months ended
	June 30, 2019		June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	230	$	458
Operating cash flows from financing leases		10		13
Financing cash flows from financing leases		89		124
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		-		240
Right-of-use assets obtained in exchange for finance lease obligations		82		1,249

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:

	June 30, 2019
Operating Leases
Right-of-use assets	$	3,685

Current lease liabilities		746
Non-current lease liabilities		3,266
Total operating lease liabilities	$	4,012


Finance Leases
Right-of-use assets	$	1,462

Current lease liabilities		448
Non-current lease liabilities		930
Total finance lease liabilities	$	1,378

Summary of Lease Term and Discount Rate

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5.11
Weighted-average remaining lease term—finance leases	3.46

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.24	%
Weighted-average discount rate—finance leases	2.86	%

Schedule of Minimum Lease Payments by Period Expected

As of June 30, 2019, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2019 (excluding the six months ended June 30, 2019)	$	240		$	465
2020		454			957
2021		325			928
2022		324			903
2023		94			543
Thereafter		4			815
Total Minimum Lease Payments		1,441			4,611
Less: imputed interest		(63	)		(599	)
Present Value of Lease Liabilities	$	1,378		$	4,012

Schedule of Minimum Lease Payments under Non-Cancelable Operating Leases

As of December 31, 2018, minimum lease payments under non-cancelable operating leases by period were expected to be as follows:

2019	$	903
2020		902
2021		877
2022		850
2023		506
Thereafter		737
	$	4,775

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Summary of Reconciliation of Changes in Stockholders' Equity

Reconciliation of the changes in stockholders' equity for the three and six months ended June 30, 2019 and 2018
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2018		61,276		$	—	$	401,273		$	(18,706	)	$	(99,189	)	$	283,378
Common stock issued upon exercise of options		4			—		22			—			—			22
Vesting of restricted stock and performance stock units		664			—		—			—			—			—
Purchase and retirement of common shares		(277	)		—		(3,595	)		—			—			(3,595	)
Compensation cost for restricted stock		—			—		653			—			—			653
Compensation cost for stock option grants		—			—		324			—			—			324
Compensation cost for performance stock units		—			—		254			—			—			254
Net loss		—			—		—			—			(3,258	)		(3,258	)
Currency translation adjustments										2,232						2,232
Unrealized gain on marketable securities		—			—		—			497			—			497
Balance at March 31, 2019		61,667		$	—	$	398,931		$	(15,977	)	$	(102,447	)	$	280,507
Common stock issued upon exercise of options		18			—		147			—			—			147
Vesting of restricted stock and performance stock units		51			—		—			—			—			—
Purchase and retirement of common shares		(11	)		—		(109	)		—			—			(109	)
Compensation cost for restricted stock		—			—		874			—			—			874
Compensation cost for stock option grants		—			—		311			—			—			311
Compensation cost for performance stock units		—			—		(569	)		—			—			(569	)
Net income		—			—		—			—			4,398			4,398
Currency translation adjustments										2,476						2,476
Unrealized gain on marketable securities		—			—		—			186			—			186
Balance at June 30, 2019		61,725		$	—	$	399,585		$	(13,315	)	$	(98,049	)	$	288,221


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2017		60,662		$	—	$	387,931		$	(10,340	)	$	(119,510	)	$	258,081

Adoption of ASU 2014-9													(75	)		(75	)
Common stock issued upon exercise of options		133			—		974			—			—			974
Vesting of restricted stock and performance stock units		407			—		—			—			—			—
Purchase and retirement of common shares		(149	)		—		(2,959	)		—			—			(2,959	)
Compensation cost for restricted stock		—			—		3,626			—			—			3,626
Compensation cost for stock option grants		—			—		900			—			—			900

Compensation cost for performance stock units		—			—		2,957			—			—			2,957
Net loss		—			—		—			—			(2,119	)		(2,119	)
Currency translation adjustments										(2,154	)					(2,154	)
Unrealized loss on marketable securities		—			—		—			(512	)		—			(512	)
Balance at March 31, 2018		61,053		$	—	$	393,429		$	(13,006	)	$	(121,704	)	$	258,719
Adoption of ASU 2014-9																—
Common stock issued upon exercise of options		29			—		222			—			—			222
Vesting of restricted stock and performance stock units		106			—		—			—			—			—
Purchase and retirement of common shares		(14	)		—		(212	)		—			—			(212	)
Compensation cost for restricted stock		—			—		1,419			—			—			1,419
Compensation cost for stock option grants		—			—		475			—			—			475

Compensation cost for performance stock units		—			—		1,885			—			—			1,885
Net income		—			—		—			—			4,121			4,121
Currency translation adjustments										(1,652	)					(1,652	)
Unrealized gain on marketable securities		—			—		—			194			—			194
Balance at June 30, 2018		61,174		$	—	$	397,218		$	(14,464	)	$	(117,583	)	$	265,171

Business Segment Information (Tables)

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three and six months ended June 30, 2019 and 2018, and asset information as of June 30, 2019 and December 31, 2018:

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019			2018
Net revenues:
OSUR	$	20,372	$	24,341		$	38,605		$	46,365
DNAG		18,454		19,284			30,343			39,247
Total	$	38,826	$	43,625		$	68,948		$	85,612
Operating income (loss):
OSUR	$	14	$	(2,666	)	$	(3,485	)	$	(11,310	)
DNAG		5,271		8,224			4,959			16,370
Total	$	5,285	$	5,558		$	1,474		$	5,060
Depreciation and amortization:
OSUR	$	844	$	993		$	1,666		$	2,004
DNAG		1,040		885			1,944			1,742
Total	$	1,884	$	1,878		$	3,610		$	3,746
Capital expenditures:
OSUR	$	1,616	$	1,358		$	3,545		$	2,774
DNAG		1,269		1,229			1,968			1,710
Total	$	2,885	$	2,587		$	5,513		$	4,484

	June 30, 2019		December 31, 2018
Total assets:
OSUR	$	173,390	$	190,178
DNAG		154,075		125,393
Total	$	327,465	$	315,571

The Company - Additional Information (Detail)	6 Months Ended
The Company - Additional Information (Detail)	Jun. 30, 2019 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 114,235	$ 113,803
Gross Unrealized Gains	230	0
Gross Unrealized Losses	(464)	(917)
Fair Value	114,001	112,886
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	24,193	23,096
Gross Unrealized Gains	0	0
Fair Value	24,193	23,096
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	90,042	90,707
Gross Unrealized Gains	230	0
Gross Unrealized Losses	(464)	(917)
Fair Value	89,808	$ 89,790
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	74,710
Gross Unrealized Gains	141
Gross Unrealized Losses	(405)
Fair Value	74,446
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	39,525
Gross Unrealized Gains	89
Gross Unrealized Losses	(59)
Fair Value	$ 39,555

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 04, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 72,567		$ 72,567				$ 88,438
Fair value of plan assets	4,227		4,227				3,884
Accumulated depreciation of property and equipment	45,040		45,040				42,797
Accumulated amortization of intangible assets	21,984		21,984				20,105
Intangible Assets, Net	12,472		12,472				5,137
Intangible Assets, Accumulated Amortization			1,228
Amount of goodwill at period end	29,280		29,280				18,521
Increase in goodwill associated with foreign currency translation			765
Right-of-use assets						$ 4,027
Lease liabilities						$ 4,263
Net foreign exchange gains (losses)	(317)	$ 91	(926)	$ 345
Accumulated foreign currency adjustments included in other comprehensive loss amounted	13,081		13,081				17,789
Unrealized loss on marketable securities	$ 234		$ 234				917
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation	698	210	222	205
Corebiome [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Foreign currency translation			$ 8,400
Novosanis [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Foreign currency translation			163
Corebiome Inc. and Novosanis NV [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amount of goodwill at period end					$ 9,994
Goodwill, acquired during period			$ 9,994
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets			5 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets			15 years
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 7,399		$ 7,399				$ 21,631

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventory Net [Abstract]
Raw materials	$ 15,551	$ 14,092
Work in process	650	544
Finished goods	9,469	8,252
Inventories	$ 25,670	$ 22,888

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Net income	$ 4,398	$ (3,258)	$ 4,121	$ (2,119)	$ 1,140	$ 2,002
Weighted-average shares of common stock outstanding:
Basic	61,709		61,100		61,621	60,983
Dilutive effect of stock options, restricted stock, and performance stock units	419		1,144		570	1,396
Diluted	62,128		62,244		62,191	62,379
Basic	$ 0.07		$ 0.07		$ 0.02	$ 0.03
Diluted	$ 0.07		$ 0.07		$ 0.02	$ 0.03

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
	Jan. 04, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current		$ 649				$ 649
Revenues		38,826		$ 43,625		68,948	$ 85,612
Net losses		(4,398)	$ 3,258	$ (4,121)	$ 2,119	(1,140)	$ (2,002)
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Purchase price	$ 13,320
Acquisition-related costs						597
Business acquisition contingent consideration, non-current		32,400				$ 32,400
Business combination contingent consideration expected payment period						3 years
Estimated fair value of contingent consideration	$ 4,350
Business acquisition contingent consideration		5,898				$ 5,898
Revenues		907				2,046
Net losses		$ 1,112				$ 2,613

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 04, 2019	Dec. 31, 2018
Assets Acquired
Goodwill	$ 29,280		$ 18,521
Corebiome Inc. and Novosanis NV [Member]
Assets Acquired
Accounts receivable		$ 791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		9,994
Total assets acquired		19,996
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		445
Other long-term liabilities		74
Total liabilities assumed		2,429
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350)
Net Cash Paid (net of cash acquired of $103)		$ 13,217

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Thousands		6 Months Ended
	Jan. 04, 2019	Jun. 30, 2019
Business Acquisition [Line Items]
Net of cash acquired	$ 103	$ 13,217

Business Combinations - Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives (Detail) - Corebiome Inc. and Novosanis NV [Member] $ in Thousands	Jan. 04, 2019 USD ($)
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 8,400
Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 5,000
Acquired intangibles, Estimated Useful Life	10 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 2,200
Acquired intangibles, Estimated Useful Life	10 years
Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 1,200
Acquired intangibles, Estimated Useful Life	8 years 4 months 2 days

Business Combinations - Summary of Unaudited Pro Forma Financial Information (Detail) - Corebiome Inc. and Novosanis NV [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Business Acquisition [Line Items]
Revenue	$ 38,826	$ 44,129	$ 68,948	$ 86,522
Net income (loss)	$ 4,398	$ 3,179	$ 1,737	$ (314)
Net income (loss) per share, basic and diluted	$ 0.07	$ 0.05	$ 0.03	$ (0.01)

Revenues - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Net revenues	$ 38,826	$ 43,625	$ 68,948	$ 85,612
Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	37,267	38,818	65,599	77,136
Product Revenues [Member] \| OraQuick [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	12,967	15,791	24,557	28,796
Product Revenues [Member] \| Oragene [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	10,904	14,421	15,726	30,349
Product Revenues [Member] \| ORAcollect [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	3,318	947	6,543	2,107
Product Revenues [Member] \| Intercept [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,070	2,154	3,914	4,069
Product Revenues [Member] \| Histofreezer [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,935	1,973	5,149	4,327
Product Revenues [Member] \| Other Products [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	5,073	3,532	9,710	7,488
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,559	4,807	3,349	8,476
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,114	2,092	2,198	3,694
Other [Member] \| Research and Development Funding [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	441	1,920	862	3,458
Other [Member] \| Charitable Support Reimbursement [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		$ 795	118	$ 1,324
Other [Member] \| Grant Funding [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 4		$ 171

Revenues - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Net revenues	$ 38,826	$ 43,625	$ 68,948	$ 85,612
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	27,902	31,991	48,467	62,977
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,990	2,308	5,421	5,205
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 7,934	$ 9,326	$ 15,060	$ 17,430

Revenues - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
Revenues - Additional Information (Detail) $ in Thousands	Jun. 30, 2019 USD ($) Supplier	Jun. 30, 2018	Jun. 30, 2019 USD ($) Supplier	Jun. 30, 2018	Dec. 31, 2018 USD ($)
Revenue from contract with customer [Line Items]
Deferred revenue	$ 3,914		$ 3,914		$ 3,521
Long-term Contract [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	1,623		1,623		1,464
Up Front Payment Arrangement [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	$ 2,291		$ 2,291		$ 2,057
DNA Genotek [Member]
Revenue from contract with customer [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier	2		2
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk			0.00%		0.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	13.00%	18.00%	0.00%	21.00%

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 5,413	$ 8,926
Professional fees	1,160	1,541
Income taxes payable		1,447
Other	2,065	1,947
Accrued Expenses, Total	$ 8,638	$ 13,861

Leases - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate		true
Lessee operating and financing leases, period of options to terminate		1 year
Lessee, operating and finance lease, existence of option to extend		true
Lease cost	$ 388		$ 730
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms		1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms		8 years

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Lease Cost [Abstract]
Operating Lease Cost	$ 232	$ 463
Finance Lease Cost
Amortization of right-of use assets	113	152
Interest on lease liabilities	9	13
Total Finance Lease Cost	$ 122	$ 165

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 230	$ 458
Operating cash flows from financing leases	10	13
Financing cash flows from financing leases	89	124
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		240
Right-of-use assets obtained in exchange for finance lease obligations	$ 82	$ 1,249

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) $ in Thousands	Jun. 30, 2019 USD ($)
Operating Leases
Right-of-use assets	$ 3,685
Current lease liabilities	746
Non-current lease liabilities	3,266
Total operating lease liabilities	4,012
Finance Leases
Right-of-use assets	1,462
Current lease liabilities	448
Non-current lease liabilities	930
Total finance lease liabilities	$ 1,378

Leases - Summary of Lease Term and Discount Rate (Detail)	Jun. 30, 2019
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5 years 1 month 9 days
Weighted-average remaining lease term—finance leases	3 years 5 months 15 days
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.24%
Weighted-average discount rate—finance leases	2.86%

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) $ in Thousands	Jun. 30, 2019 USD ($)
Finance Lease Liabilities, Payments, Due [Abstract]
2019 (excluding the six months ended June 30, 2019)	$ 240
2020	454
2021	325
2022	324
2023	94
Thereafter	4
Total Minimum Finance Lease Payments	1,441
Less: imputed interest	(63)
Present Value of Finance Lease Liabilities	1,378
Operating Lease Liabilities, Payments Due [Abstract]
2019 (excluding the six months ended June 30, 2019)	465
2020	957
2021	928
2022	903
2023	543
Thereafter	815
Total Minimum Operating Lease Payments	4,611
Less: imputed interest	(599)
Present Value of Operating Lease Liabilities	$ 4,012

Leases - Schedule of Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 903
2020	902
2021	877
2022	850
2023	506
Thereafter	737
Total	$ 4,775

Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Beginning Balance	$ 280,507	$ 283,378	$ 258,719	$ 258,081	$ 283,378	$ 258,081
Adoption of ASU 2014-9				(75)
Common stock issued upon exercise of options	147	22	222	974
Purchase and retirement of common shares	(109)	(3,595)	(212)	(2,959)
Compensation cost for restricted stock	874	653	1,419	3,626
Compensation cost for stock option grants	311	324	475	900
Compensation cost for performance stock units	(569)	254	1,885	2,957
Net income (loss)	4,398	(3,258)	4,121	(2,119)	1,140	2,002
Currency translation adjustments	2,476	2,232	(1,652)	(2,154)	4,708	(3,806)
Unrealized gain (loss) on marketable securities	186	497	194	(512)	683	(318)
Ending Balance	$ 288,221	$ 280,507	$ 265,171	$ 258,719	$ 288,221	$ 265,171
Common Stock [Member]
Beginning Balance, Shares	61,667	61,276	61,053	60,662	61,276	60,662
Common stock issued upon exercise of options, Shares	18	4	29	133
Vesting of restricted stock and performance stock units, Shares	51	664	106	407
Purchase and retirement of common shares, Shares	(11)	(277)	(14)	(149)
Ending Balance, Shares	61,725	61,667	61,174	61,053	61,725	61,174
Additional Paid-in Capital [Member]
Beginning Balance	$ 398,931	$ 401,273	$ 393,429	$ 387,931	$ 401,273	$ 387,931
Common stock issued upon exercise of options	147	22	222	974
Purchase and retirement of common shares	(109)	(3,595)	(212)	(2,959)
Compensation cost for restricted stock	874	653	1,419	3,626
Compensation cost for stock option grants	311	324	475	900
Compensation cost for performance stock units	(569)	254	1,885	2,957
Ending Balance	399,585	398,931	397,218	393,429	399,585	397,218
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(15,977)	(18,706)	(13,006)	(10,340)	(18,706)	(10,340)
Currency translation adjustments	2,476	2,232	(1,652)	(2,154)
Unrealized gain (loss) on marketable securities	186	497	194	(512)
Ending Balance	(13,315)	(15,977)	(14,464)	(13,006)	(13,315)	(14,464)
Accumulated Deficit [Member]
Beginning Balance	(102,447)	(99,189)	(121,704)	(119,510)	(99,189)	(119,510)
Adoption of ASU 2014-9				(75)
Net income (loss)	4,398	(3,258)	4,121	(2,119)
Ending Balance	$ (98,049)	$ (102,447)	$ (117,583)	$ (121,704)	$ (98,049)	$ (117,583)

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ 1,848,000	$ 11,262,000
Amount share repurchase program of common shares				$ 25,000,000
Retiring President and Chief Executive Officer and Chief Financial Officer [Member] \| General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 2,188,000		8,039,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		635,000	1,375,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ 1,527,000	$ 5,045,000
Vesting of restricted shares, withholding and exercise obligations		288,000	163,000
Restricted shares of common stock, aggregate values		$ 3,704,000	$ 3,171,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ (315,000)	$ 4,842,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		0	0

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income tax expense	$ 1,411,000	$ 2,173,000	$ 1,382,000	$ 4,206,000
U.S. federal or state deferred income tax expense or benefits	$ 0		$ 0

Transition Costs - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
General and Administrative Expenses [Member]
Transition Costs [Line Items]
Non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company's new President and CEO	$ 0	$ 2,188,000	$ 0	$ 8,628,000

Business Segment Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2019 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net revenues	$ 38,826	$ 43,625	$ 68,948	$ 85,612
Operating income (loss)	5,285	5,558	1,474	5,060
Depreciation and amortization	1,884	1,878	3,610	3,746
Capital expenditures	2,885	2,587	5,513	4,484
Total assets	327,465		327,465		$ 315,571
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues	20,372	24,341	38,605	46,365
Operating income (loss)	14	(2,666)	(3,485)	(11,310)
Depreciation and amortization	844	993	1,666	2,004
Capital expenditures	1,616	1,358	3,545	2,774
Total assets	173,390		173,390		190,178
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues	18,454	19,284	30,343	39,247
Operating income (loss)	5,271	8,224	4,959	16,370
Depreciation and amortization	1,040	885	1,944	1,742
Capital expenditures	1,269	$ 1,229	1,968	$ 1,710
Total assets	$ 154,075		$ 154,075		$ 125,393